SCHEMBL5322970

SCHEMBL5322970

CC1(c2ccc(OCC(=O)NCc3ccc(NS(C)(=O)=O)c(F)c3)cc2F)SCCS1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5324780 0.89
SCHEMBL5274662 0.85
SCHEMBL4640525 0.84 TRPV1 (0.47)
SCHEMBL5322537 0.84 SMN1; SMN2 (0.38)
SCHEMBL4640618 0.82 HPGD (0.50)
SCHEMBL5281260 0.82 SMN1; SMN2 (0.64)
SCHEMBL5276305 0.82 GRIN1 (0.52)
SCHEMBL5325377 0.81
SCHEMBL14397117 0.81
SCHEMBL4641852 0.81 TRPV1 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007120012-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-10-25 WO claimed
WO-2007120012-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-10-25 WO disclosed